Nevertheless, T790M negative cases after re-biopsy are currently being treated according to the first-line treatment of NSCLC without driver mutation (e.g., EGFR, ALK (anaplastic lymphoma kinase), ROS1). This evidence concerns the gene ALK and non-small cell lung carcinoma.